Clinical Trials
178 trialsNCT06132113 2026-05-27
DAREONâ„¢-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers
Boehringer Ingelheim
Phase 1 Recruiting
NCT06487481 2026-05-27
Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT07080242 2026-05-22
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
SystImmune Inc.
Phase 1 Recruiting
NCT07189403 2026-05-22
A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer
Daiichi Sankyo
Phase 1 Recruiting
NCT04514497 2026-05-19
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06122610 2026-05-15
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
University of Wisconsin, Madison
Phase 1 Recruiting
NCT04750954 2026-05-13
Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06379217 2026-05-11
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
Novartis
Phase 1 Active not recruiting
NCT00004847 2026-05-07
Diagnosis of Pheochromocytoma
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT05599984 2026-05-07
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
AbbVie
Phase 1 Active not recruiting
NCT02088645 2026-05-01
Lumed
University Hospital, Basel, Switzerland
Phase 1 Active not recruiting
NCT03465618 2026-05-01
A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT06441331 2026-05-01
KinLET
ITM Solucin GmbH
Phase 1 Recruiting
NCT04234568 2026-04-30
Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT07488923 2026-04-29
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
Moonlight Bio, Inc
Phase 1 Not yet recruiting
NCT06479811 2026-04-28
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT06889493 2026-04-28
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
University of Miami
Phase 1 Recruiting
NCT07485569 2026-04-15
REPOTHYROID-II
Radboud University Medical Center
Phase 1 Not yet recruiting
NCT04375267 2026-04-14
LuPARP
Vastra Gotaland Region
Phase 1 Completed
NCT05142189 2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1 Recruiting
NCT06941480 2026-04-14
A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate
Memorial Sloan Kettering Cancer Center
Phase 1 Not yet recruiting
NCT05249114 2026-04-13
Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
Providence Health & Services
Phase 1 Active not recruiting
NCT07165132 2026-04-13
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
RayzeBio, Inc.
Phase 1 Recruiting
NCT03975231 2026-04-08
Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT06041516 2026-03-27
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT05680922 2026-03-24
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
Legend Biotech USA Inc
Phase 1 Active not recruiting
NCT04119024 2026-03-17
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Phase 1 Recruiting
NCT02402920 2026-03-10
Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT07456878 2026-03-09
Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas
Mayo Clinic
Phase 1 Recruiting
NCT04895748 2026-03-03
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
Phase 1 Terminated
NCT06910657 2026-03-02
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
Phase 1 Recruiting
NCT07150546 2026-03-02
Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.
Emory University
Phase 1 Recruiting
NCT03833700 2026-02-27
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
Eisai Inc.
Phase 1 Active not recruiting
NCT04459273 2026-02-05
FAPI PET RDRC
Jonsson Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT07369505 2026-01-27
Sapu003 in Advanced mTOR-sensitive Solid Tumors
SAPU NANO (US) LLC
Phase 1 Recruiting
NCT07366658 2026-01-26
NEUK203-13
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1 Not yet recruiting
NCT05556473 2026-01-23
F-Tryptophan PET/CT in Human Cancers
Barbara Ann Karmanos Cancer Institute
Phase 1 Recruiting
NCT03746431 2026-01-07
A Phase 1 Study of [225Ac]-FPI-1434 Injection
Fusion Pharmaceuticals Inc.
Phase 1 Terminated
NCT07287748 2025-12-31
A Phase I Trial of Af-001 in Patients With Differentiated Thyroid Cancer
Alpha Fusion Inc.
Phase 1 Recruiting
NCT07252661 2025-11-28
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
AccSalus Biosciences, Inc.
Phase 1 Not yet recruiting
NCT05178693 2025-11-24
LANTana
Imperial College London
Phase 1 Recruiting
NCT05364944 2025-11-17
OXTEND-01
Debiopharm International SA
Phase 1 Terminated
NCT06902376 2025-11-05
NEO-COMBATXL
UNC Lineberger Comprehensive Cancer Center
Phase 1 Recruiting
NCT07181720 2025-10-02
CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
Chongqing Precision Biotech Co., Ltd
Phase 1 Recruiting
NCT06805825 2025-09-23
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Novelty Nobility, Inc.
Phase 1 Recruiting
NCT06505824 2025-09-18
A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT06577987 2025-09-15
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Circle Pharma
Phase 1 Recruiting
NCT04702737 2025-09-12
DeLLpro-300
Amgen
Phase 1 Completed
NCT04609592 2025-09-09
Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
Stanford University
Phase 1 Recruiting
NCT04462471 2025-09-08
Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
Memorial Sloan Kettering Cancer Center
Phase 1 Completed